Asian Journal Of Social Pharmacy

Abstract: Objective To provide reference for improving Chinese innovative drug research and development incentive policies. Methods Based on investigating the incentive policies for innovative drug research and development in clinical research, evaluation and approval in China, anti-tumor drugs were taken as the research object to discuss relevant policies from the perspective of clinical trials and registration approval based on data statistics and current situation analysis. Results and Conclusion Driven by a series of incentive policies for innovative drug R&D, great achievements have been made on anti-tumor drugs. However, there are problems such as concentration of drug targets, homogenization of clinical trials, and gaps in some drugs with large clinical needs. To improve incentive policies for innovative drug R&D, China should adhere to the orientation of clinical value, focusing on basic research and translational research, improving evaluation and approval capabilities, and establishing a sound ecosystem for innovative drugs.

Key words: innovative drug, innovative anti-tumor drug, incentive policy, policy analysis